Steven P. Treon

33.5k total citations · 7 hit papers
471 papers, 19.3k citations indexed

About

Steven P. Treon is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Steven P. Treon has authored 471 papers receiving a total of 19.3k indexed citations (citations by other indexed papers that have themselves been cited), including 414 papers in Genetics, 249 papers in Pathology and Forensic Medicine and 141 papers in Immunology. Recurrent topics in Steven P. Treon's work include Chronic Lymphocytic Leukemia Research (412 papers), Lymphoma Diagnosis and Treatment (237 papers) and Immunodeficiency and Autoimmune Disorders (94 papers). Steven P. Treon is often cited by papers focused on Chronic Lymphocytic Leukemia Research (412 papers), Lymphoma Diagnosis and Treatment (237 papers) and Immunodeficiency and Autoimmune Disorders (94 papers). Steven P. Treon collaborates with scholars based in United States, Italy and France. Steven P. Treon's co-authors include Kenneth C. Anderson, Zachary R. Hunter, Dharminder Chauhan, Teru Hideshima, Paul G. Richardson, Lian Xu, Jorge J. Castillo, Guang Yang, Christopher J. Patterson and Nicholas Mitsiades and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Steven P. Treon

449 papers receiving 18.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

2012 795 citations Steven P. Treon, Lian Xu et al. profile →
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

2001 740 citations Teru Hideshima, Yu‐Tzu Tai et al. Blood profile →
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

2000 708 citations Teru Hideshima, Yu‐Tzu Tai et al. Blood profile →
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

2003 621 citations Roger G. Owen, Steven P. Treon et al. profile →
Molecular sequelae of proteasome inhibition in human multiple myeloma cells

2002 597 citations Steven P. Treon, Nikhil C. Munshi et al. profile →
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

2002 544 citations Constantine S. Mitsiades, Paul G. Richardson et al. Blood profile →
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader

2017 330 citations Guang Yang, Steven P. Treon et al. profile →

Peers

Countries citing papers authored by Steven P. Treon

Since Specialization

Citations

This map shows the geographic impact of Steven P. Treon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven P. Treon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven P. Treon more than expected).

Fields of papers citing papers by Steven P. Treon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven P. Treon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven P. Treon. The network helps show where Steven P. Treon may publish in the future.

Co-authorship network of co-authors of Steven P. Treon

This figure shows the co-authorship network connecting the top 25 collaborators of Steven P. Treon. A scholar is included among the top collaborators of Steven P. Treon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven P. Treon. Steven P. Treon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease 2025 ·Seminars in Hematology ·Prashant Kapoor, Meletios Α. Dimopoulos, Stephen M. Ansell, Efstathios Kastritis, Ranjana H. Advani, Éric Durot, Pierre Morel, Charalampia Kyriakou, Roman Hájek, Daniela Drandi, Jithma P. Abeykoon, Signy Chow, (unknown), Christopher J. Patterson, Jeffrey Matous, Christian Buske, Steven P. Treon, Marie José Kersten	1
2	Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors 2025 ·Seminars in Hematology ·Jorge J. Castillo, Francesco Autore, Neil L. Berinstein, Andrew R. Branagan, Meletios Α. Dimopoulos, Carlos Fernández de Larrea, Simone Ferrero, Prashant Kapoor, Efstathios Kastritis, Jahanzaib Khwaja, Monique C. Minnema, Lugui Qiu, John F. Seymour, Josephine M. I. Vos, Christopher J. Patterson, Christian Buske, Jeffrey Matous, Steven P. Treon, M. Lia Palomba	0
3	Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia 2025 ·Seminars in Hematology ·Shayna Sarosiek, (unknown), Andrew R. Branagan, Simone Ferrero, Jahanzaib Khwaja, Eva Kimby, Damien Roos‐Weil, Naohiro Sekiguchi, Marek Trněný, Shuhua Yi, Christopher J. Patterson, Christian Buske, Jeffrey Matous, Steven P. Treon, Monique C. Minnema	0
4	Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia 2024 ·Blood Advances ·(unknown), Jorge J. Castillo, Shayna Sarosiek, Andrew R. Branagan, Catherine Flynn, Kirsten Meid, Joshua Gustine, Xia Liu, Amanda Kofides, Shirong Liu, (unknown), Katherine Kacena, Christopher J. Patterson, Maria Luisa Guerrera, Nicholas Tsakmaklis, Steven P. Treon, Zachary R. Hunter	1
5	BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia. 2024 ·Journal of Clinical Oncology ·(unknown), Stephen Opat, John Hrom, David Kliman, Paula Marlton, (unknown), (unknown), (unknown), Jun Zhang, Haiyi Guo, Steven P. Treon	3
6	High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia 2024 ·Blood ·Éric Durot, Damien Roos‐Weil, Adrien Chauchet, Justine Decroocq, Roberta Di Blasi, Thomas Gastinne, (unknown), Morgane Cheminant, (unknown), Stéphanie Guidez, François‐Xavier Gros, Emmanuel Bachy, (unknown), Pascale Cony‐Makhoul, Steven P. Treon, Alain Delmer, Ran Reshef, Steven Le Gouill, Jorge J. Castillo, Roch Houot	3
7	Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia 2022 ·International Journal of Cancer ·Dana Cholujová, (unknown), Zachary R. Hunter, Teru Hideshima, Ludmila M. Flores, (unknown), (unknown), (unknown), Merav Leiba, Ľuboš Drgoňa, Steven P. Treon, Efstathios Kastritis, David M. Dorfman, Kenneth C. Anderson, Jana Jakubı́ková	5
8	Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial 2021 ·Clinical Cancer Research ·Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios Α. Dimopoulos	27
9	Epigenetic Targeting of Waldenström Macroglobulinemia Cells with Bet Inhibitors Synergizes with BCl2 or Histone Deacetylase Inhibition 2020 ·Epigenomics ·(unknown), Weiguo Han, (unknown), (unknown), Brendan M. Reilly, (unknown), (unknown), Manit Munshi, Guang Yang, Steven P. Treon, Sarah R. Walker, Sherine F. Elsawa	7
10	Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 2018 ·Clinical Cancer Research ·(unknown), Fazal Shirazi, Veerabhadran Baladandayuthapani, Heather Lin, Isere Kuiatse, Hua Wang, Richard J. Jones, Zuzana Berkova, Yasumichi Hitoshi, Stephen M. Ansell, Steven P. Treon, Sheeba K. Thomas, Hans C. Lee, Zhiqiang Wang, R. Eric Davis, Robert Z. Orlowski	14
11	Investigation and management of IgM and Waldenström‐associated peripheral neuropathies: recommendations from the IWWM ‐8 consensus panel 2017 ·British Journal of Haematology ·Shirley D’Sa, Marie José Kersten, Jorge J. Castillo, Meletios Α. Dimopoulos, Efstathios Kastritis, Edward Laane, Véronique Leblond, Giampaolo Merlini, Steven P. Treon, Josephine M. I. Vos, Michael P. Lunn	47
12	Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes 2016 ·British Journal of Haematology ·Josephine M. I. Vos, Joshua Gustine, Helmut G. Rennke, Zachary R. Hunter, Robert Manning, Toni Dubeau, Kirsten Meid, Monique C. Minnema, Marie José Kersten, Steven P. Treon, Jorge J. Castillo	56
13	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells 2015 ·Clinical Cancer Research ·Julie S. Nielsen, (unknown), Aniqa Shahid, Zusheng Zong, Zabrina L. Brumme, Stephen Yu, Lewis Liu, David R. Kroeger, Steven P. Treon, Joseph M. Connors, Randy D. Gascoyne, Brian Berry, Marco A. Marra, Ryan D. Morin, Nicol Macpherson, Brad H. Nelson	18
14	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia 2015 ·Clinical Cancer Research ·Isere Kuiatse, Veerabhadran Baladandayuthapani, Heather Lin, Sheeba K. Thomas, Chad C. Bjorklund, Donna M. Weber, Michael Wang, Jatin J. Shah, Xing‐Ding Zhang, Richard J. Jones, Stephen M. Ansell, Guang Yang, Steven P. Treon, Robert Z. Orlowski	16
15	Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia 2014 ·Blood ·Steven P. Treon, Yang Cao, Lian Xu, Guang Yang, Xia Liu, Zachary R. Hunter	241
16	miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway 2014 ·Cancer Research ·Jianjun Zhao, Jianhong Lin, Di Zhu, Xujun Wang, Daniel J. Brooks, Ming Chen, (unknown), Kohichi Takada, Bryan Ciccarelli, (unknown), Jianguo Tao, Yu‐Tzu Tai, Steven P. Treon, Geraldine Pinkus, Winston Patrick Kuo, Teru Hideshima, Mary Bouxsein, Nikhil C. Munshi, Kenneth C. Anderson, Ruben D. Carrasco	159
17	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. 2014 ·UCL Discovery (University College London) ·Meletios Α. Dimopoulos, Efstathios Kastritis, Roger G. Owen, Robert A. Kyle, Ola Landgren, (unknown), Xavier Leleu, Nikhil C. Munshi, Kenneth C. Anderson, (unknown), Irene M. Ghobrial, (unknown), David G. Maloney, (unknown), Ranjana H. Advani, Morie A. Gertz, (unknown), Sheeba K. Thomas, (unknown), (unknown), (unknown), (unknown), Steven P. Treon, (unknown), (unknown)	0
18	Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma 2012 ·Molecular Cancer Therapeutics ·Douglas W. McMillin, Hannah M. Jacobs, Jake Delmore, Leutz Buon, Zachary R. Hunter, (unknown), Jie Yu, Peter G. Smith, Paul G. Richardson, Kenneth C. Anderson, Steven P. Treon, Andrew L. Kung, Constantine S. Mitsiades	46
19	Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia 2010 ·Journal of Clinical Oncology ·Irene M. Ghobrial, Morie A. Gertz, Betsy LaPlant, John Camoriano, Suzanne R. Hayman, Martha Q. Lacy, Stacey Chuma, Brianna Harris, Renee Leduc, Meghan Rourke, Stephen M. Ansell, Daniel J. DeAngelo, Angela Dispenzieri, Leif Bergsagel, Craig B. Reeder, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Thomas E. Witzig	102
20	International prognostic scoring system for Waldenström macroglobulinemia 2009 ·Blood ·Pierre Morel, Alain Duhamel, Paolo G. Gobbi, Meletios Α. Dimopoulos, Madhav V. Dhodapkar, Jason McCoy, John Crowley, Enrique M. Ocio, Ramón García‐Sánz, Steven P. Treon, Véronique Leblond, Robert A. Kyle, Bart Barlogie, Giampaolo Merlini	228

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact